Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression? Anastasia GeladarisSebastian TorkeMartin S. Weber Leading Article Open access 30 September 2022 Pages: 1019 - 1030
A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review Niloufar PouyanZahra Halvaei KhankahdaniRoger S. McIntyre Systematic Review Open access 12 September 2022 Pages: 1031 - 1047
Psychotropic Drugs and Adverse Kidney Effects: A Systematic Review of the Past Decade of Research Joseph Junior DambaKatie BodensteinKyle T. Greenway Systematic Review 26 September 2022 Pages: 1049 - 1077
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies Adam StrzelczykSusanne Schubert-Bast Review Article Open access 04 October 2022 Pages: 1079 - 1111
Eslicarbazepine Acetate as Adjunctive Therapy for Primary Generalized Tonic-Clonic Seizures in Adults: A Prospective Observational Study Yaroslav WinterKatharina SandnerSergiu Groppa Original Research Article Open access 30 September 2022 Pages: 1113 - 1119
Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) and Natalizumab Serum Concentration as Potential Biomarkers for Pharmacodynamics and Treatment Response of Patients with Multiple Sclerosis Receiving Natalizumab Michael AuerAngelika BauerFlorian Deisenhammer Original Research Article 29 September 2022 Pages: 1121 - 1131
Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder Tina NieHannah A. Blair Adis Drug Evaluation Open access 07 September 2022 Pages: 1133 - 1141